Genome And Company A Leading Global Microbiome Anti-Cancer Drug Development Company, Announced It Has Entered Into A First Clinical Trial Collaboration And Supply Agreement (Ctcsa) With Msd (A Tradename Of Merck & Co., Inc., Kenilworth, N.J., Usa).Upon The Execution Of The Agreement, Genome And Company Will Conduct A Phase 2 Clinical Trial To Evaluate The Safety And Efficacy Of Its Immuno-Oncology Microbiome Therapeutic, 'Gen-001', In Combination With Msd'S Anti-Pd-1 Therapy, Keytruda
